[1] |
Jockenhöfer F, Wollina U, Salva KA, et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum[J]. Br J Dermatol, 2019,180(3):615⁃620. doi: 10.1111/bjd.16401.
|
[2] |
Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a delphi consensus of international experts[J]. JAMA Dermatol, 2018,154(4):461⁃466. doi: 10.1001/jamadermatol.2017.5980.
|
[3] |
Xu A, Balgobind A, Strunk A, et al. Prevalence estimates for pyoderma gangrenosum in the United States: an age⁃ and sex⁃adjusted population analysis[J]. J Am Acad Dermatol, 2020,83(2):425⁃429. doi: 10.1016/j.jaad.2019.08.001.
|
[4] |
Monari P, Moro R, Motolese A, et al. Epidemiology of pyoderma gangrenosum: results from an Italian prospective multicentre study[J]. Int Wound J, 2018,15(6):875⁃879. doi: 10.1111/iwj. 12939.
|
[5] |
Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study[J]. J Invest Dermatol, 2012,132(9):2166⁃2170. doi: 10.1038/jid.2012.130.
|
[6] |
江燕云, 李骥, 李玥, 等. 溃疡性结肠炎并发坏疽性脓皮病八例研究[J]. 中华皮肤科杂志, 2017,50(9):623⁃625. doi: 10. 3760/cma.j.issn.0412⁃4030.2017.09.001.
|
[7] |
Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta⁃analysis[J]. Am J Clin Dermatol, 2018,19(4):479⁃487. doi: 10.1007/s40257⁃018⁃0356⁃7.
|
[8] |
Card TR, Langan SM, Chu TP. Extra⁃gastrointestinal manifestations of inflammatory bowel disease may be less common than previously reported[J]. Dig Dis Sci, 2016,61(9):2619⁃2626. doi: 10.1007/s10620⁃016⁃4195⁃1.
|
[9] |
Ashchyan HJ, Butler DC, Nelson CA, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum[J]. JAMA Dermatol, 2018,154(4):409⁃413. doi: 10.1001/jamadermatol.2017.5978.
|
[10] |
Weenig RH, Davis MD, Dahl PR, et al. Skin ulcers misdiagnosed as pyoderma gangrenosum[J]. N Engl J Med, 2002,347(18):1412⁃1418. doi: 10.1056/NEJMoa013383.
|
[11] |
Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria[J]. Int J Dermatol, 2004,43(11):790⁃800. doi: 10.1111/j.1365⁃4632.2004.02128.x.
|
[12] |
Haag C, Hansen T, Hajar T, et al. Comparison of three diagnostic frameworks for pyoderma gangrenosum[J]. J Invest Dermatol, 2021,141(1):59⁃63. doi: 10.1016/j.jid.2020.04.019.
|
[13] |
Binus AM, Qureshi AA, Li VW, et al. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients[J]. Br J Dermatol, 2011,165(6):1244⁃1250. doi: 10.1111/j.1365⁃2133.2011.10565.x.
|
[14] |
Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum[J]. Nat Rev Dis Primers, 2020,6(1):81. doi: 10.1038/s41572⁃020⁃0213⁃x.
|
[15] |
Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi⁃systematic review[J]. Int Wound J, 2019,16(2):511⁃521. doi: 10.1111/iwj.13067.
|
[16] |
Wu Z, Xu QY, Yao ZR. Recalcitrant pediatric pyoderma gangrenosum controlled with adalimumab[J]. Int J Dermatol Venereol, 2022:10.1097/JD9.0000000000000258. doi: 10.1097/JD9.0000000000000258.
|
[17] |
Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin⁃1 receptor antagonist anakinra[J]. Br J Dermatol, 2009,161(5):1199⁃1201. doi: 10.1111/j.1365⁃2133.2009.09404.x.
|
[18] |
Jaeger T, Andres C, Grosber M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa⁃⁃rapid response to canakinumab (anti⁃IL⁃1β)[J]. Eur J Dermatol, 2013,23(3):408⁃410. doi: 10.1684/ejd.2013.2018.
|
[19] |
Greb JE, Gottlieb AB, Goldminz AM. High⁃dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum[J]. Dermatol Ther, 2016,29(6):482⁃483. doi: 10.1111/dth.12387.
|